183 related articles for article (PubMed ID: 37874259)
1. Early Cancer Detection in Li-Fraumeni Syndrome with Cell-Free DNA.
Wong D; Luo P; Oldfield LE; Gong H; Brunga L; Rabinowicz R; Subasri V; Chan C; Downs T; Farncombe KM; Luu B; Norman M; Sobotka JA; Uju P; Eagles J; Pedersen S; Wellum J; Danesh A; Prokopec SD; Stutheit-Zhao EY; Znassi N; Heisler LE; Jovelin R; Lam B; Lujan Toro BE; Marsh K; Sundaravadanam Y; Torti D; Man C; Goldenberg A; Xu W; Veit-Haibach P; Doria AS; Malkin D; Kim RH; Pugh TJ
Cancer Discov; 2024 Jan; 14(1):104-119. PubMed ID: 37874259
[TBL] [Abstract][Full Text] [Related]
2. Is It Time to Incorporate Liquid Biopsy into High-Risk Cancer Surveillance Protocols in Li-Fraumeni Syndrome?
Latham A; MacFarland SP; Walsh MF; Maxwell KN; Stadler ZK
Cancer Discov; 2024 Jan; 14(1):23-25. PubMed ID: 38213298
[TBL] [Abstract][Full Text] [Related]
3. Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome.
Kratz CP; Achatz MI; Brugières L; Frebourg T; Garber JE; Greer MC; Hansford JR; Janeway KA; Kohlmann WK; McGee R; Mullighan CG; Onel K; Pajtler KW; Pfister SM; Savage SA; Schiffman JD; Schneider KA; Strong LC; Evans DGR; Wasserman JD; Villani A; Malkin D
Clin Cancer Res; 2017 Jun; 23(11):e38-e45. PubMed ID: 28572266
[TBL] [Abstract][Full Text] [Related]
4. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.
Kumamoto T; Yamazaki F; Nakano Y; Tamura C; Tashiro S; Hattori H; Nakagawara A; Tsunematsu Y
Int J Clin Oncol; 2021 Dec; 26(12):2161-2178. PubMed ID: 34633580
[TBL] [Abstract][Full Text] [Related]
5. Multiple Germline Events Contribute to Cancer Development in Patients with Li-Fraumeni Syndrome.
Subasri V; Light N; Kanwar N; Brzezinski J; Luo P; Hansford JR; Cairney E; Portwine C; Elser C; Finlay JL; Nichols KE; Alon N; Brunga L; Anson J; Kohlmann W; de Andrade KC; Khincha PP; Savage SA; Schiffman JD; Weksberg R; Pugh TJ; Villani A; Shlien A; Goldenberg A; Malkin D
Cancer Res Commun; 2023 May; 3(5):738-754. PubMed ID: 37377903
[TBL] [Abstract][Full Text] [Related]
6. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome.
Kamihara J; Rana HQ; Garber JE
Hum Mutat; 2014 Jun; 35(6):654-62. PubMed ID: 24706533
[TBL] [Abstract][Full Text] [Related]
7. Li-Fraumeni syndrome in Tunisian carriers with different and rare tumor phenotype: genotype-phenotype correlation.
Sassi H; Meddeb R; Cherif MA; Nasr C; Riahi A; Hannachi S; Belguith N; M'rad R
BMC Med Genomics; 2022 Mar; 15(1):44. PubMed ID: 35246108
[TBL] [Abstract][Full Text] [Related]
8. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
[TBL] [Abstract][Full Text] [Related]
9. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.
de Andrade KC; Khincha PP; Hatton JN; Frone MN; Wegman-Ostrosky T; Mai PL; Best AF; Savage SA
Lancet Oncol; 2021 Dec; 22(12):1787-1798. PubMed ID: 34780712
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.
Villani A; Shore A; Wasserman JD; Stephens D; Kim RH; Druker H; Gallinger B; Naumer A; Kohlmann W; Novokmet A; Tabori U; Tijerin M; Greer ML; Finlay JL; Schiffman JD; Malkin D
Lancet Oncol; 2016 Sep; 17(9):1295-305. PubMed ID: 27501770
[TBL] [Abstract][Full Text] [Related]
11. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
[TBL] [Abstract][Full Text] [Related]
12. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.
Bojadzieva J; Amini B; Day SF; Jackson TL; Thomas PS; Willis BJ; Throckmorton WR; Daw NC; Bevers TB; Strong LC
Fam Cancer; 2018 Apr; 17(2):287-294. PubMed ID: 28988289
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of TP53 germline variants and their correlations with Li-Fraumeni syndrome or Li-Fraumeni-like syndrome in Chinese tumor patients.
Tian P; Zhang X; Yang S; Fang Y; Yuan H; Li W; Zhu H; Zhao F; Ding J; Zhu Y; Wang S; Sun G; Ni H; Ma T; Lei T
J Genet Genomics; 2022 Jul; 49(7):645-653. PubMed ID: 35033608
[TBL] [Abstract][Full Text] [Related]
14. Inherited
Guha T; Malkin D
Cold Spring Harb Perspect Med; 2017 Apr; 7(4):. PubMed ID: 28270529
[TBL] [Abstract][Full Text] [Related]
15. Surveillance imaging and early surgical intervention for improved CNS tumor outcomes in children with Li-Fraumeni syndrome: Children's National Hospital experience and literature review.
Patel N; Felton K; Bhattacharya S; Almira-Suarez MI; Eze A; Turner J; Keating R; Oluigbo C; Schore RJ; Kilburn L; Packer RJ; Myseros JS; Bornhorst M
J Neurosurg Pediatr; 2023 Mar; 31(3):258-267. PubMed ID: 36609372
[TBL] [Abstract][Full Text] [Related]
16. Paired Tumor-Normal Sequencing Provides Insights Into the TP53-Related Cancer Spectrum in Patients With Li-Fraumeni Syndrome.
Ceyhan-Birsoy O; Selenica P; Chui MH; Jayakumaran G; Ptashkin R; Misyura M; Aypar U; Jairam S; Yang C; Li Y; Mehta N; Kemel Y; Salo-Mullen E; Maio A; Sheehan M; Zehir A; Carlo M; Latham A; Stadler Z; Robson M; Offit K; Ladanyi M; Walsh M; Reis-Filho JS; Mandelker D
J Natl Cancer Inst; 2021 Nov; 113(12):1751-1760. PubMed ID: 34240179
[TBL] [Abstract][Full Text] [Related]
17. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
Fortuno C; James PA; Spurdle AB
Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
[TBL] [Abstract][Full Text] [Related]
19. Clinical and molecular characterization of patients fulfilling Chompret criteria for Li-Fraumeni syndrome in Southern Brazil.
Matzenbacher Bittar C; de Araújo Rocha YM; Vieira IA; Rosset C; Andreis TF; Sartor ITS; Artigalás O; Netto CBO; Alemar B; Macedo GS; Ashton-Prolla P
PLoS One; 2021; 16(9):e0251639. PubMed ID: 34529667
[TBL] [Abstract][Full Text] [Related]
20. The profile and contribution of rare germline copy number variants to cancer risk in Li-Fraumeni patients negative for TP53 mutations.
Silva AG; Krepischi AC; Pearson PL; Hainaut P; Rosenberg C; Achatz MI
Orphanet J Rare Dis; 2014 Apr; 9():63. PubMed ID: 24775443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
